| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1473-3099(08)70018-5 |
| P698 | PubMed publication ID | 18222164 |
| P50 | author | Christopher J. Schofield | Q21165677 |
| Alex John O'Neill | Q53770069 | ||
| Ian Chopra | Q105819967 | ||
| Keith Miller | Q40739161 | ||
| Mark H. Wilcox | Q47356567 | ||
| P2093 | author name string | Patrice Courvalin | |
| Jean-Marie Frère | |||
| Uros Urleb | |||
| Martin Everett | |||
| Lloyd Czaplewski | |||
| Mike Dawson | |||
| P2860 | cites work | Antibacterial discovery and development--the failure of success? | Q47825932 |
| Lack of development of new antimicrobial drugs: a potential serious threat to public health | Q48002635 | ||
| Surveillance of antimicrobial resistance of invasive pathogens: the Estonian experience | Q50061144 | ||
| Resistance in gram-negative bacteria: Enterobacteriaceae. | Q51187082 | ||
| Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme MurD. | Q52860325 | ||
| Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005. | Q53249223 | ||
| Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. | Q53250268 | ||
| Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. | Q53883952 | ||
| Design, synthesis and structure-activity relationships of new phosphinate inhibitors of MurD. | Q54475713 | ||
| Design, synthesis, biochemical evaluation and antimycobacterial action of phosphonate inhibitors of antigen 85C, a crucial enzyme involved in biosynthesis of the mycobacterial cell wall | Q58040446 | ||
| Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report | Q63859723 | ||
| Serious Infections in the Intensive Care Unit: Pseudomonas aeruginosa and Acinetobacter baumannii | Q63859736 | ||
| Where have all the antibiotic patents gone? | Q79423620 | ||
| Old polymyxins are back: is resistance close? | Q80052849 | ||
| Biomedical research. A cure for medicine's ailments? | Q83018524 | ||
| Antimicrobial resistance: paradox, actions and economics | Q83177259 | ||
| Drug discovery in jeopardy | Q22306297 | ||
| Comparative genomics of multidrug resistance in Acinetobacter baumannii | Q25256737 | ||
| The glycylcyclines: a comparative review with the tetracyclines | Q28238716 | ||
| Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa | Q28256421 | ||
| Antimicrobial drug development--the past, the present, and the future | Q34364369 | ||
| Overview of nosocomial infections caused by gram-negative bacilli | Q34444001 | ||
| The biological cost of mutational antibiotic resistance: any practical conclusions? | Q34554396 | ||
| Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa | Q34555131 | ||
| The worldwide emergence of plasmid-mediated quinolone resistance | Q34569740 | ||
| Exploiting current understanding of antibiotic action for discovery of new drugs. | Q34631418 | ||
| Quinupristin-dalfopristin and linezolid: evidence and opinion | Q34648292 | ||
| The future challenges facing the development of new antimicrobial drugs. | Q34988239 | ||
| Why is big Pharma getting out of antibacterial drug discovery? | Q35565576 | ||
| Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures | Q35917130 | ||
| The need for new antibiotics | Q35937137 | ||
| Antibacterial drug discovery in the 21st century | Q35937143 | ||
| Antibacterial drug discovery: is it all downhill from here? | Q35937148 | ||
| Antimicrobial drug resistance, regulation, and research | Q36026412 | ||
| Mechanisms of action of newer antibiotics for Gram-positive pathogens | Q36081079 | ||
| Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat | Q36108084 | ||
| Tigecycline | Q36205663 | ||
| Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria | Q36228587 | ||
| Can biotech deliver new antibiotics? | Q36242043 | ||
| The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! | Q36242554 | ||
| Resistance to antibiotics: are we in the post-antibiotic era? | Q36282569 | ||
| Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America | Q36382134 | ||
| Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance | Q36552514 | ||
| Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia | Q36559388 | ||
| The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? | Q36634360 | ||
| Anti-infective research and development--problems, challenges, and solutions | Q36689490 | ||
| New lipophilic phthalimido- and 3-phenoxybenzyl sulfonates: inhibition of antigen 85C mycolyltransferase activity and cytotoxicity | Q40216674 | ||
| Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques | Q40289356 | ||
| Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem | Q40290852 | ||
| Sampling the antibiotic resistome | Q40357052 | ||
| (Genome) size matters | Q41896915 | ||
| Phosphonate inhibitors of antigen 85C, a crucial enzyme involved in the biosynthesis of the Mycobacterium tuberculosis cell wall | Q44921136 | ||
| Antimicrobials: new solutions badly needed | Q44962251 | ||
| Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3'')-Ii/AAC(6')-IId from Serratia marcescens | Q46337932 | ||
| A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli | Q46699876 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| P433 | issue | 2 | |
| P921 | main subject | Gram-negative bacteria | Q632006 |
| P304 | page(s) | 133-139 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Lancet Infectious Diseases | Q15724248 |
| P1476 | title | Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement | |
| P478 | volume | 8 |
| Q58216000 | 5-Benzylidenethiazolidin-4-ones as Multitarget Inhibitors of Bacterial Mur Ligases |
| Q34045186 | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane |
| Q26783545 | A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics |
| Q28543574 | A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids |
| Q38008459 | Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models |
| Q82430538 | An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates |
| Q36322582 | Antibacterial and antibiotic resistance modulatory activities of leaves and bark extracts of Recinodindron heudelotii (Euphorbiaceae) against multidrug-resistant Gram-negative bacteria |
| Q38475604 | Antibacterial effect and proteomic analysis of graphene-based silver nanoparticles on a pathogenic bacterium Pseudomonas aeruginosa. |
| Q90617651 | Antimicrobial Resistance Prediction for Gram-Negative Bacteria via Game Theory-Based Feature Evaluation |
| Q35757930 | Antimicrobial activity of different Lactobacillus species against multi- drug resistant clinical isolates of Pseudomonas aeruginosa. |
| Q42003874 | Antimicrobial activity of the marine alkaloids, clathrodin and oroidin, and their synthetic analogues |
| Q38222114 | Antimicrobial peptides from scorpion venoms |
| Q41837042 | Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms |
| Q64268541 | Approaches to the Structure-Based Design of Antivirulence Drugs: Therapeutics for the Post-Antibiotic Era |
| Q41923916 | Bacterial and antimicrobial susceptibility profile and the prevalence of sepsis among burn patients at the burn unit of Cipto Mangunkusumo Hospital |
| Q29616084 | Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America |
| Q37894832 | Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria |
| Q37760510 | Changes in the incidences of multidrug-resistant and extensively drug-resistant organisms isolated in a military medical center |
| Q53657637 | Characterization and sensitivity to antibiotics of bacteria isolated from the lower respiratory tract of ventilated patients hospitalized in intensive care units. |
| Q30726683 | Could chloramphenicol be used against ESKAPE pathogens? A review of in vitro data in the literature from the 21st century |
| Q36206767 | Crystallization and preliminary diffraction studies of SFC-1, a carbapenemase conferring antibiotic resistance |
| Q92398568 | Decoding inflammation, its causes, genomic responses, and emerging countermeasures |
| Q36652863 | Design, Synthesis and Evaluation of Triazole-Pyrimidine Analogues as SecA Inhibitors. |
| Q36649317 | Development of new 5-(chromene-3-yl)methylene-2,4-thiazolidinediones as antimicrobial agents |
| Q42100896 | Efficient Catalyst One-Pot Synthesis of 7-(Aryl)-10,10-dimethyl-10,11-dihydrochromeno[4,3-b]chromene-6,8(7H,9H)-dione Derivatives Complemented by Antibacterial Activity |
| Q40886052 | Efflux Pump Blockers in Gram-Negative Bacteria: The New Generation of Hydantoin Based-Modulators to Improve Antibiotic Activity |
| Q57777225 | Enhancement of antimicrobial activity by co-administration of poly(propylene imine) dendrimers and nadifloxacin |
| Q34357575 | Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead |
| Q34517482 | From microbial gene essentiality to novel antimicrobial drug targets |
| Q37487101 | Genome Sequence of Bacteriophage GG32, Which Can Infect both Salmonella enterica Serovar Typhimurium and Escherichia coli O157:H7 |
| Q37355097 | Hospital infections, animal models and alternatives |
| Q34114983 | Hospital-acquired infections due to gram-negative bacteria |
| Q28475476 | How beta-lactam antibiotics enter bacteria: a dialogue with the porins |
| Q34215398 | In silico identification of common putative drug targets in Leptospira interrogans |
| Q48564199 | Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps |
| Q38986360 | Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective. |
| Q39776788 | New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging. |
| Q28475848 | New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors |
| Q37767653 | New definitions of extended-spectrum β-lactamase conferring worldwide emerging antibiotic resistance |
| Q33422956 | New disturbing trend in antimicrobial resistance of gram-negative pathogens |
| Q37287855 | Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection |
| Q37792479 | Polymyxins and their novel derivatives |
| Q36033050 | Prevalence of Device-associated Nosocomial Infections Caused By Gram-negative Bacteria in a Trauma Intensive Care Unit in Libya |
| Q34136100 | Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia |
| Q28486100 | Pseudomonas aeruginosa PA1006 is a persulfide-modified protein that is critical for molybdenum homeostasis |
| Q60915100 | ROS mediated antibacterial activity of photoilluminated riboflavin: A photodynamic mechanism against nosocomial infections |
| Q27677114 | Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid |
| Q38793887 | Role of Phenothiazines and Structurally Similar Compounds of Plant Origin in the Fight against Infections by Drug Resistant Bacteria |
| Q37872942 | Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria |
| Q38646502 | Structural and Enzymatic Characterization of ABgp46, a Novel Phage Endolysin with Broad Anti-Gram-Negative Bacterial Activity |
| Q33605661 | Structure-based discovery of antibacterial drugs |
| Q36791550 | Surveillance of multidrug resistant uropathogenic bacteria in hospitalized patients in Indian |
| Q39937286 | Synthesis and antimicrobial activities of 5-Arylidene-thiazolidine-2,4-dione derivatives. |
| Q54332036 | Synthesis and antimicrobial activities of oximes derived from O-benzylhydroxylamine as FabH inhibitors. |
| Q42871255 | Synthesis of new chalcone derivatives containing a rhodanine-3-acetic acid moiety with potential anti-bacterial activity |
| Q35021444 | Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones. |
| Q37518925 | Targeting bacterial adherence inhibits multidrug-resistant Pseudomonas aeruginosa infection following burn injury |
| Q58742314 | Targeting the Bacterial Protective Armour; Challenges and Novel Strategies in the Treatment of Microbial Biofilm |
| Q34374054 | The "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation |
| Q37786162 | The Dilemma of Multidrug-Resistant Gram-Negative Bacteria |
| Q28484507 | The binding mode of second-generation sulfonamide inhibitors of MurD: clues for rational design of potent MurD inhibitors |
| Q59485638 | The crisis of no new antibiotics—what is the way forward? |
| Q39862670 | The cyclotide cycloviolacin O2 from Viola odorata has potent bactericidal activity against Gram-negative bacteria |
| Q34310470 | The enzymes of β-lactam biosynthesis |
| Q36825533 | The growing resistance of Klebsiella pneumoniae; the need to expand our antibiogram: case report and review of the literature. |
| Q41978763 | The target of daptomycin is absent from Escherichia coli and other gram-negative pathogens |
| Q38810063 | Using Chemical Probes to Assess the Feasibility of Targeting SecA for Developing Antimicrobial Agents against Gram-Negative Bacteria. |
| Q33897752 | Virtual screening for potential inhibitors of homology modeled Leptospira interrogans MurD ligase |
Search more.